Senior Correspondent, London
Ben's Feed
Sep 17, 2014
Sep 17, 2014

For Roche CEO, celebrating failure is key to success

LONDON, Sept 17 (Reuters) – Roche Chief Executive
Severin Schwan likes to crack open the champagne with his drug
research teams at the end of a big project – especially when
they fail.

As the boss of one of the world’s most successful
pharmaceutical companies, whose leading position in cancer
treatments has propelled its market value to more than $250
billion, it might seem a strange response.

Sep 16, 2014
Sep 16, 2014

Roche’s $8 billion InterMune buy not a signal for more big deals

LONDON (Reuters) – Roche’s (ROG.VX: Quote, Profile, Research, Stock Buzz) decision to buy U.S. biotech company InterMune (ITMN.O: Quote, Profile, Research, Stock Buzz) for $8.3 billion last month was “exceptional” and not a sign of more ambitious plans for major acquisitions, the Swiss drugmaker’ s chief executive said on Tuesday.

Damping down expectations that Roche could embark on a series of such multibillion-dollar deals to bolster its presence in the treatment of rare diseases, Severin Schwan told Reuters there was no change in the company’s M&A strategy or its likely pace of deal-making.

Sep 16, 2014
Sep 16, 2014
Sep 16, 2014
Sep 16, 2014

AstraZeneca gets up to $500 million from Lilly for Alzheimer’s drug

LONDON (Reuters) – AstraZeneca has signed a partnership deal with U.S. rival Eli Lilly that could earn the British company up to $500 million if a promising – but risky – experimental Alzheimer’s drug proves successful.

AstraZeneca said in May that it was looking to find a partner for its so-called BACE inhibitor drug called AZD3293, which is set to enter late-stage Phase III clinical testing against Alzheimer’s.

Sep 15, 2014
Sep 15, 2014
    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben